Portfolio
Current Investments
We founded this inflammation focused company in February 2018 and raised a Series A in February 2020.Flame completed a $100mm crossover raise in October 2020. The company was sold to Leap Therapeutics in 2023.
In 2016, Torreya co-founded Bond Biosciences with an inventor from Kansas University. The company is focused on non-absorbed chelators (similar to ZS Pharma) with a focus on treating iron overload disorders. The company completed a $10mm Series B financing in 2022.
Glint Biosciences is a San Diego based company developing a device for the detection of multiple analytes in complex fluids such as blood using a novel detection technology based on synthetic biology and photonics. Glint raised a seed round in late 2021 with Emerald acting as a lead investor.
Health Outlook provides better predictions of longevity and health events than are currently available. Health Outlook partners with financial services companies and health systems. Health Outlook is also working on algorithms to help extend human lifespans. Company raised $9mm in a seed round in 2023 anchored by Petrichor and Avego.
Software platform that allows users to create an e-prescribing web site in a few days.
Focused on building out a network of clinics with physician partners focused on women’s health.
Built around a mAb against a novel checkpoint target in the PVR axis for cancer.
Built around a novel set of FcRn bispecifics for autoimmunity.
Built around a novel approach to treat breast cancer based on iNOS inhibition.